Picture two men who each drop 30 pounds, starting at the same baseline weight and finishing at the same ending weight.
But the DEXA scan reveals a big difference between the men:
One of them is revealed to be leaner and stronger than when he started.
The other one is somehow fatter and weaker.
So what’s up with the scale giving the same reading but the bodies telling a completely different story?
You already know the answer, but allow me to say it out loud: The first man protected his muscle as the fat came off while the second man didn’t.
It had nothing to do with the drugs they used.
However, the pharmaceutical industry is betting billions on the creation of a compound that will automatically allow for the preservation of muscle mass without the need for resistance training or high protein intake.
It goes by the name of Bimagrumab, and while it is promising on paper, almost nobody in mainstream medicine is explaining its utility properly.
And that’s where this article comes in.
Quick Takeaways
- Bimagrumab blocks the receptor that your muscle tissue uses to limit its own growth, meaning it operates on a completely different mechanism than GLP-1 peptides.
- Human trials show simultaneous fat loss AND lean mass gain in addition to less muscle loss.
- GLP-1 peptides are not inherently catabolic, and the muscle loss blamed on them is almost always attributable to failures around training and nutrition protocols.
- Bimagrumab is still investigational and available only inside clinical trials; therefore, understanding the mechanism matters more right now than chasing unauthorized access.
What Bimagrumab Actually Is
Bimagrumab is a monoclonal antibody originally developed by Novartis to treat muscle wasting conditions like sarcopenia.
It was later picked up by Versanis Bio, which Eli Lilly acquired back in 2023, once researchers realized it was melting fat AND building muscle in the early preclinical studies.
In the clinical trials, it’s given as an intravenous infusion ranging anywhere from every few weeks to every few months.
But what deserves your full attention tight now is the fact a pharmacological solution to simultaneous muscle gain and fat loss involving a single drug may exist in the near future.
The Myostatin Pathway
Myostatin (also called GDF-8) is a protein your body produces to limit muscle growth, which was first discovered when myostatin-null mice developed dramatically more muscle in early studies.
It works by binding to activin type II receptors (ActRIIA and ActRIIB) on muscle cells, effectively instructing those cells to stop growing.
Bimagrumab binds those receptors itself and blocks myostatin, along with activin A and GDF-11, from ever attaching to the receptors.
As a result, there is no signal reaching the muscle cell that tells it to halt its growth.
This is fundamentally different from how anabolic steroids or SARMs work, which push growth signals forward.
To use a car metaphor: Instead of pressing the gas pedal, Bimagrumab works by removing your foot from the brake.
But if you were paying attention, you’ll remember we blocked the receptor entirely… which means in addition to myostatin not being able to bind to it, every other ligand that uses the receptor will meet the same fate.
This is the same broad-blockade approach that ultimately sank ACE-031, which I break down in my article comparing follistatin vs myostatin inhibitors.
Why Mainstream Weight Loss Medicine Gets This Wrong
GLP-1 peptides like Semaglutide, Tirzepatide, and Retatrutide work primarily by suppressing appetite, slowing gastric emptying, reducing glucagon secretion and improving insulin signaling.
That mechanism doesn’t build muscle but it doesn’t destroy it either.
As I lay out in my book Metabolic Awakening with GLP-1 Peptides, there is nothing inherently catabolic about receptor agonism to GLP-1, GIP, or glucagon with respect to muscle tissue.
The lean mass losses seen in GLP-1 trials track closely with the roughly 3:1 fat-to-fat-free-mass ratio seen in any well-controlled weight loss program, with or without the use of drugs.
And “lean mass” on a DEXA includes water and organ tissue in addition to muscle tissue, which means a drop in lean mass is NOT automatically equivalent to a drop in skeletal muscle.
The real failure of mainstream obesity medicine comes from prescribing doses that are way too high and sending people home with zero guidance on protein, resistance training, electrolyte supplementation or assessing body composition.
Weight loss and fat loss are not the same thing, but for some odd reason the medical establishment keeps conflating them despite this knowledge being freely available for decades.
Bimagrumab exposes this blind spot because it changes what your fat and muscle tissue actually do at the cellular level.
The Mechanism: How Bimagrumab Rewires Fat and Muscle
Blocking ActRII does indeed affect muscle tissue, but that’s not where its biological mechanism of action ends.
In mice, antibody blockade of ActRIIB activates brown fat thermogenesis, thereby expanding brown adipose tissue and raising whole-body energy expenditure.
When myostatin and activin signaling gets blocked, here’s what ensues:
- Muscle protein synthesis increases
- Muscle cells become more metabolically active, leading to more glucose and fatty acids being burned for energy
- Brown fat thermogenesis and whole-body energy expenditure appear to be elevated
- Fat mass drops as a downstream consequence of the body exerting a greater metabolic demand
So in addition to adding muscle, you’re also creating a physiological state where more fuel is burned to maintain the muscle.
That is a completely different physiological strategy compared to caloric restriction or appetite suppression, and it’s the same reason visceral fat becomes so much easier to lose once lean tissue mass starts rising.
What The Research Actually Shows
A trial published in JAMA Network Open by Rooks and colleagues in 2020 gave Bimagrumab to adults over 70 with sarcopenia for 24 weeks, and found it added roughly 2 kg of lean mass while leading to a drop of 3 kg of fat compared to placebo.
But both groups were given a protocol for nutrition and exercise at home, which is why physical function improved for the placebo group and the Bimagrumab-using group.
So even though the drug added mass, the lifestyle foundation is what led to improvements in function.
A separate trial from Heymsfield and colleagues, published in JAMA Network Open a year later, studied Bimagrumab in adults with type 2 diabetes and obesity over 48 weeks.
Participants lost about 21% of body fat while simultaneously gaining lean mass, compared to almost no change on placebo.
Then, in 2026, the BELIEVE trial published in Nature Medicine combined Bimagrumab with Semaglutide over 72 weeks.
Semaglutide alone produced 15.7% weight loss, with roughly 72% of it coming from fat.
The combination of Semaglutide and Bimagrumab pushed weight loss to 22.1%, with nearly 93% of it coming from fat.
So while the catastrophic flaw with poor GLP-1 use isn’t fully fixed, adding in Bimagrumab appears to shift a decent ratio of fat loss into something worth bragging about.
Myth vs Reality
| Myth | Reality |
| “All fat loss drugs cause muscle loss” | GLP-1 peptides aren’t inherently catabolic, and bimagrumab adds lean mass on top of fat loss |
| “Myostatin inhibitors are just for bodybuilders” | The pathway has documented metabolic and fat-reducing effects |
| “This is basically like GLP-1 drugs” | Completely different receptor, completely different mechanism |
| “No human data exists” | Multiple published human trials exist, and the data set is still being built |
My Take After Years Watching This Space
I’ve been tracking myostatin inhibition since the early SARM and follistatin experiments conducted over a decade ago.
Most of those approaches were crude and poorly targeted, but the major issue is they came with side effects nobody wanted to talk about.
Bimagrumab is the most important pharmaceutical validation the myostatin-inhibition pathway has ever received, because it proves in human trials what bodybuilders and biohackers have long suspected for years: Take the brake off muscle growth inhibition, and fat loss follows.
Nevertheless, it’s still a blunt pharmacological instrument.
Blocking the entire receptor also shuts down activin signaling, which governs FSH and reproductive hormones, and that’s exactly why I favor the selective activin-sparing approach of FLGR-242 versus Follistatin-344.
A lot of people are mistakenly ignoring FLGR-242 because they assume a drug requires FDA approval for a specific indication before the mechanism is worth understanding and studying.
My response is simple: The dataset is still being built, and the fact we’re in the early stages of FLGR-242 doesn’t automatically mean it’s unsafe.
I’d rather understand a mechanism thoroughly and make an informed decision with a qualified physician instead of waiting a decade for the FDA to catch up to biology it cannot profit from “managing.”
Comparison: Bimagrumab vs Other Recomposition Approaches
| Compound | Primary Mechanism | Effect on Muscle | Effect on Fat |
| Bimagrumab | ActRII receptor blockade (myostatin, activins, GDF-11) | Increases | Decreases |
| FLGR-242 | Activin-sparing myostatin neutralization | Increases | Decreases |
| GLP-1 peptides | Appetite suppression, insulin signaling | Preserved with proper training and protein | Decreases |
| Anabolic steroids | Androgen receptor activation | Increases | Variable |
| Caloric restriction without training | Energy deficit | Decreases | Decreases |
This table alone should tell you why the myostatin pathway is generating so much attention in optimization circles.
The two approaches that build muscle and burn fat at the same time without an external androgenic growth signal both work by taking the foot off the brake.
Safety, Risks, and Contraindications
I am not a doctor, and I AM NOT telling you to run out and source Bimagrumab on your own.
Reported side effects in the trials have included diarrhea, muscle spasms, liver enzyme increases, infections in the upper respiratory area, and acne.
Since this drug blocks a fundamental growth-regulating pathway, there are open questions about long-term effects on connective tissue, cardiac muscle, vascular integrity, and other tissues that also express the ActRII receptor.
Bimagrumab is still investigational, so the only legitimate way to access it right now is through a clinical trial.
Furthermore, anyone who wants to explore this pathway has to work with a physician who understands muscle physiology and endocrinology at a sophisticated level.
The way I see it right now, any experimentation with myostatin pathway compounds without physician oversight and proper lab monitoring is borderline reckless.
Who This Actually Matters For
Men over 35 losing muscle mass while simultaneously accumulating visceral fat are the population who stand to benefit most from understanding this mechanism, and I explain why that muscular decline accelerates in my breakdown of sarcopenia after 50.
This is the exact demographic getting failed by conventional weight loss advice where the “calorie in, calorie out” model treats your energy intake as the only variable that matters.
For women, the activin connection matters even more because activin signaling helps regulate FSH and ovarian function… both of which are impacted by the broad receptor blockade.
My wife Monica’s approach with women is always to choose ONE goal, start low, go up slowly, and only when it’s necessary to do so… and her guide to the best peptides for women over 40 is the best starting point before anything this advanced is ever considered.
Women considering this category of compound require a practitioner who understands female hormonal architecture like the back of their hands.
Health Sovereignty Is the Real Takeaway Here
Understanding mechanisms such as the blockade of ActRII puts the power back in your hands, even if the compound itself isn’t accessible to everyone today.
Your job is to stay educated and stay skeptical of oversimplified fat loss narratives.
Most importantly, with or without this compound, find an optimization-minded physician who will discuss these mechanisms with you.
I’ll keep tracking Bimagrumab and the next generation of myostatin pathway compounds as the data matures.
If you want the unfiltered truth as it develops, join my email list to stay updated.
Isn’t It Time You Became Fully Optimized To Live Leaner, Longer And Stronger?
Join my #1 online membership group, Fully Optimized Health to receive guidance from me and an elite group of more than 800 male and female biohackers (who all started out just like you).
And don’t forget to check out our other premium educational content dedicated to helping you fully optimize your health:
Live Leaner, Longer, Stronger: The 2026 God Stack Masterclass: the exact stack I run today, from therapeutic testosterone and FLGR242 to α-Klotho and Retatrutide. Five compounds, 26 years of self-experimentation, zero theory.
The Ultimate GLP-1 Video Masterclass: how to PROPERLY use the world’s most powerful fat loss drugs to lose fat, keep your muscle, and improve your longevity.
The Positive Muscle Failure Video Training Method: three filmed full-body workouts with Monica and me that teach you to train to failure, not to exhaustion, for maximum muscle in minimum time.
Monica Campbell’s Ultimate 3-Day Training Program: my wife Monica’s full-body program for women ready to build real strength, sculpt lean muscle, and train with intensity.
The 30 Days 2 Shredz Video Masterclass: reprogram your mind and metabolism to torch fat with our Optimized Fasting Protocol, without the hunger and willpower battles.
Raise Your Vibration: the dimension of health that biohacking always misses. Monica and I walk you through the five pillars of a high-frequency life, grounded in the data.
See you on the inside!
[Disclaimer: This article is for educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before beginning any peptide or hormonal protocol.]
